Imagion (ASX:IBX) share price up 1,166% in a year pursuing ‘radiation-free’ cancer tech

The Imagion Biosystems Ltd (ASX: IBX) share price has rocketed 1,166% over the past 12 months due to a series of promising projects around cancer detection.

The company’s bio is truly a mouthful: its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and – the clincher — superparamagnetic relaxometry. 

What investors should know is that it develops medical devices focused around cancer screening technology.

Imagion’s Magsense cancer screening technology

One of these tech projects, called Magsense, is a diagnostic imaging tool that can potentially increase…